Lineage Cell Therapeutics, Inc. Share Price
Stocks
LCTX
US53566P1093
Biotechnology & Medical Research
|
Real-time Estimate
Cboe BZX
07:15:07 22/10/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 0.9600 USD | +0.89% |
|
+3.71% | -43.02% |
| 01/10 | EARNINGS: Generation Essentials interim profit jumps to USD28 million | AN |
| 07/08 | Lineage Cell Therapeutics, Inc., Q2 2026 Earnings Call, Aug 06, 2026 |
| Market Cap | 24Cr 21Cr 20Cr 18Cr 34Cr 2.27TCr 34Cr 238.03Cr 93Cr 1.19TCr 90Cr 88Cr 3.8TCr | P/E 2026 * |
-15.9x | P/E 2027 * | -7.41x |
|---|---|---|---|---|---|
| Enterprise Value | 24Cr 21Cr 20Cr 18Cr 34Cr 2.27TCr 34Cr 238.03Cr 93Cr 1.19TCr 90Cr 88Cr 3.8TCr | EV / Sales 2026 * |
15.8x | EV / Sales 2027 * | 14.3x |
| Free-Float |
95.14% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
NYSE
| LCTX | Delayed | |
TEL AVIV STOCK EXCHANGE
| LCTX | Delayed | |
|
CBOE
| LCTX | Real-time | |
|
Boerse Muenchen
| BT3 | Real-time | |
|
Deutsche Boerse AG
| BT3 | Delayed | |
|
Börse Stuttgart
| BT3 | Delayed | |
|
Tradegate
| BT3 | Real-time |
Last Transcript: Lineage Cell Therapeutics, Inc.
| 1 day | -0.05% | ||
| 1 week | +3.71% | ||
| Current month | -0.44% | ||
| 1 month | -5.79% | ||
| 3 months | -16.54% | ||
| 6 months | -41.98% | ||
| Current year | -43.02% |
| 1 week | 0.94 |  | 1.01 |
| 1 month | 0.88 | | 1.04 |
| Current year | 0.88 | | 1.98 |
| 1 year | 0.88 | | 2.09 |
| 3 years | 0.37 | | 2.09 |
| 5 years | 0.37 | | 2.71 |
| 10 years | 0.37 | | 3.96 |
| Manager | Title | Age | Since |
|---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 54 | 17/09/2018 |
Jill Howe
DFI | Director of Finance/CFO | 50 | 14/11/2022 |
Priyantha Herath
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 60 | 01/07/2009 |
Deborah Andrews
BRD | Director/Board Member | 68 | 11/04/2014 |
Michael Mulroy
CHM | Chairman | 60 | 27/04/2024 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 01/07/26 | Free | Director | 1,25,000 | 0.0501% | ||
| 01/07/26 | Broadwood Capital, Inc.
| Free | Company | 1,25,000 | 0.0501% | |
| 01/07/26 | Free | Director | 1,25,000 | 0.0501% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.89% | +3.71% | -42.33% | -20.71% | 24Cr | |
| -0.21% | -4.43% | +44.40% | +74.13% | 6.62TCr | |
| +1.04% | +4.35% | +11.62% | +75.56% | 5.52TCr | |
| +1.19% | +4.37% | +12.54% | +92.37% | 5.28TCr | |
| +1.02% | +5.58% | +26.51% | +50.05% | 4.55TCr | |
| -0.90% | +9.95% | +22.40% | +133.92% | 4.39TCr | |
| -0.24% | +0.39% | +263.21% | +594.60% | 4.16TCr | |
| +0.10% | +9.90% | +16.11% | +59.33% | 3.4TCr | |
| -8.38% | -6.95% | +26.35% | -1.93% | 2.58TCr | |
| +1.35% | +4.55% | +37.71% | +27.54% | 2.35TCr | |
| Average | -0.44% | +4.04% | +41.85% | +108.49% | 3.89TCr | |
| Weighted average by Cap. | -0.12% | +3.72% | +50.14% | +127.25% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 1.52Cr 1.35Cr 1.25Cr 1.13Cr 2.14Cr 143.37Cr 2.16Cr 15Cr 5.9Cr 75Cr 5.7Cr 5.58Cr 240.14Cr | 1.68Cr 1.5Cr 1.39Cr 1.26Cr 2.37Cr 158.86Cr 2.4Cr 17Cr 6.53Cr 84Cr 6.32Cr 6.18Cr 266.09Cr |
| Net income | -2.26Cr -2.02Cr -1.87Cr -1.69Cr -3.18Cr -213.65Cr -3.22Cr -22Cr -8.79Cr -112.3Cr -8.49Cr -8.32Cr -357.86Cr | -3.44Cr -3.07Cr -2.84Cr -2.57Cr -4.84Cr -325Cr -4.9Cr -34Cr -13Cr -170.83Cr -13Cr -13Cr -544.36Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/26/22 | $0.9483 | -0.34% | 1,435 |
| 21/26/21 | $0.9515 | -2.17% | 12,20,810 |
| 20/26/20 | $0.9726 | +2.08% | 16,31,237 |
| 19/26/19 | $0.9528 | -2.61% | 9,55,552 |
| 16/26/16 | $0.9783 | -1.21% | 13,08,653 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- LCTX Stock
Select your edition
All financial news and data tailored to specific country editions
